Какова цена за TMS Co., Ltd. (4891)

Цена за TMS Co., Ltd. (4891) Это $0.73072946

Какова рыночная капитализация для TMS Co., Ltd. (4891)

Рыночная капитализация для TMS Co., Ltd. (4891) Это $33.30M

Прибыль TMS Co., Ltd. (4891)

Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The company's pipeline includes TMS-007, an SMTP congener demonstrating both prothrombolytic and anti-inflammatory/antioxidative activities, which has advanced through Phase 2a clinical trials for the treatment of acute ischemic stroke. Additionally, TMS-008, another SMTP congener with anti-inflammatory/antioxidative properties, is undergoing nonclinical development for addressing inflammatory complications like acute kidney injury and cancer cachexia. A third product candidate, TMS-009, is currently in preclinical development. TMS Co., Ltd. collaborates with Hokkaido University and Kanazawa University to assess the potential of its drug candidates, has a joint research agreement with Teikyo University to identify renal function biomarkers, and maintains a strategic alliance with Ji Xing Pharmaceuticals Limited.

Год	Прибыль	Изменить
Недостаточно данных для указанных дат.

Год

Прибыль

Изменить

Недостаточно данных для указанных дат.

Компания	Прибыль	Разница в прибыли	Страна
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Moderna, Inc. MRNA.US	$-3.09B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$1.61B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Компания

Прибыль

Разница в прибыли

Страна